Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells $1,609,860.00 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Eben Tessari sold 42,000 shares of the company’s stock in a transaction on Monday, September 29th. The shares were sold at an average price of $38.33, for a total value of $1,609,860.00. Following the completion of the transaction, the chief operating officer directly owned 34,552 shares in the company, valued at approximately $1,324,378.16. This trade represents a 54.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Eben Tessari also recently made the following trade(s):

• On Monday, September 15th, Eben Tessari sold 16,400 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $36.46, for a total transaction of $597,944.00.
• On Thursday, September 4th, Eben Tessari sold 85,271 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.52, for a total transaction of $3,028,825.92.
• On Friday, September 5th, Eben Tessari sold 13,389 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $35.66, for a total transaction of $477,451.74.
• On Wednesday, September 3rd, Eben Tessari sold 15,091 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $35.50, for a total transaction of $535,730.50.
• On Monday, August 18th, Eben Tessari sold 16,200 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $33.77, for a total transaction of $547,074.00.
• On Tuesday, August 5th, Eben Tessari sold 138,614 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $33.20, for a total transaction of $4,601,984.80.
• On Monday, July 14th, Eben Tessari sold 18,900 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $28.72, for a total value of $542,808.00.

Kiniksa Pharmaceuticals International Stock Down 0.5%

NASDAQ:KNSA opened at $38.64 on Thursday. The stock’s fifty day moving average is $34.03 and its two-hundred day moving average is $28.45. Kiniksa Pharmaceuticals International, plc has a 52 week low of $17.82 and a 52 week high of $39.12. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of 966.24 and a beta of 0.16.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The firm had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently modified their holdings of the company. EverSource Wealth Advisors LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares in the last quarter. Osaic Holdings Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at $31,000. GAMMA Investing LLC raised its stake in Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock valued at $27,000 after buying an additional 568 shares in the last quarter. US Bancorp DE acquired a new stake in Kiniksa Pharmaceuticals International in the first quarter valued at $33,000. Finally, Quantbot Technologies LP acquired a new stake in Kiniksa Pharmaceuticals International in the second quarter valued at $43,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on KNSA. Wedbush reissued an “outperform” rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Jefferies Financial Group increased their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday, July 29th. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 7th. Wells Fargo & Company increased their target price on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a report on Thursday, September 25th. Finally, TD Cowen started coverage on Kiniksa Pharmaceuticals International in a research note on Monday. They issued a “buy” rating and a $60.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $44.29.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.